Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Faran Shimi Naltrexone Methobromide

    Virtual Booth

    Contact Supplier

    Naltrexone Methobromide

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Naltrexone Methobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 8,699Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actavis`s Generics Methylnaltrexone Br. Receives Approval in US
    Actavis`s Generics Methylnaltrexone Br. Receives Approval in US

    26 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208112

    FDA
    26 Aug 2024
    Share Share
    Salix Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R)
    Salix Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R)

    06 Mar 2024

    // ACCESSWIRE

    https://www.accesswire.com/839567/salix-pharmaceuticals-announces-a-phase-2-investigator-initiated-study-of-relistor-methylnaltrexone-bromide-mntx-in-patients-with-resectable-head-and-neck-squamous-cell-carcinoma

    ACCESSWIRE
    06 Mar 2024
    Share Share
    Gland's Generic Methylnaltrexone Bromide Receives Receives Approval in the U.S.
    Gland's Generic Methylnaltrexone Bromide Receives Receives Approval in the U.S.

    05 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216836

    FDA
    05 May 2023
    Share Share
    Noramco Announces Submission & Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
    Noramco Announces Submission & Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

    01 Nov 2022

    // PRESS RELEASE

    https://www.noramco.com/2022/11/01/noramco-announces-submission-and-reactivation-of-the-drug-master-file-for-active-pharmaceutical-ingredient-methylnaltrexone-bromide/

    PRESS RELEASE
    01 Nov 2022
    Share Share
    Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting
    Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting

    24 Oct 2022

    // ACCESSWIRE

    https://www.accesswire.com/721607/Salix-Will-Present-XIFAXANR-Rifaximin-TRULANCER-Plecanatide-and-RELISTORR-Methylnaltrexone-Bromide-Data-at-The-American-College-of-GastroenterologyR-2022-Annual-Scientific-Meeting

    ACCESSWIRE
    24 Oct 2022
    Share Share
    New Data on Cost Impact of Treating OIC with FDA-Approved Medications
    New Data on Cost Impact of Treating OIC with FDA-Approved Medications

    24 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/new-data-on-cost-impact-of-treating-opioid-induced-constipation-oic-with-fda-approved-medications-including-salixs-relistor-subcutaneous-injection-methylnaltrexone-bromide-in-the-emergency-department-is-published-in-advanc-301509600.html

    PRNEWSWIRE
    24 Mar 2022
    Share Share